Trial
NCT05785390
Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Novatek Pharmaceuticals
Collaborators
—
Condition
COVID-19
Intervention
NP-101
Why stopped
The interim analysis results met protocol and SAP predetermined criteria for stopping early due to futility or efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-22